The methylation-induced silencing of p16 has been reported in 25–42% of gastric carcinomas, thus potentially serving as a biomarker for primary cancer diagnosis by predicting the malignancy of dysplastic lesions [150,151]. Here, CDKN2A is linked to cancer.